All In Biotech

Investigational drug · Phase 2

CM338

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for IgA Nephropathy.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "CM338"

First trial start

2023

May 8, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "CM338", any sponsor or status.

Conditions studied

As listed on its trial records.

  • IgA Nephropathy

Approved drugs for the same conditions: IgA nephropathy · Kidney and urology

Largest trials

Live from ClinicalTrials.gov: studies naming "CM338" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for IgA Nephropathy

  • CM313Phase 36 trials

    Keymed Biosciences Co.Ltd · Systemic Lupus Erythematosus, Primary Immune Thrombocytopenia, Platelet Transfusion Refractoriness

  • FUB523zigakibart, BION-1301Phase 36 trials

    Novartis · IgA Nephropathy, Immunoglobulin A Nephropathy, IgA Nephropathy (IgAN)

  • SCTC21CPhase 34 trials

    Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)

  • JADE101Phase 32 trials

    Jade Biosciences, Inc. · IgA Nephropathy (IgAN), IgA Nephropathy

  • BHV-1400Phase 31 trial

    Biohaven Therapeutics Ltd. · IgA Nephropathy

  • NM8074Phase 28 trials

    NovelMed Therapeutics · Paroxysmal Nocturnal Hemoglobinuria, Dermatomyositis, PNH - Paroxysmal Nocturnal Hemoglobinuria

  • XH-S003Phase 22 trials

    Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. · PNH - Paroxysmal Nocturnal Hemoglobinuria, IgA Nephropathy

  • ADX-097Phase 21 trial

    Akebia Therapeutics · IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.